Both act at the cellular level, but with different objectives
What the Research Says The bottom line: No randomized controlled trial has tested weekly tirzepatide doses below 2.5 mg for weight loss, cardiovascular benefit, or metabolic outcomes
However, in a within-group (012 wk) analysis the power raised to 0.74 for HbA1c in the MO group (results not shown), but remained low for FBG
Ro has been an extremely integral part of my weight loss journey
FDA-approved options for chronic weight management include: Other GLP-1 receptor agonists (semaglutide, liraglutide) Combination therapies (phentermine-topiramate ER, naltrexone-bupropion ER) Orlistat Metformin for patients with diabetes or prediabetes, which provides modest weight-neutral or weight-loss effects Realistic expectations are essential
Where there is significant frailty or multiple comorbidities, referral to specialist geriatric or weight management services may be appropriate, and alternative approaches to weight management may be more suitable
